Novo Nordisk A/S Cash Flow Conversion Efficiency
Novo Nordisk A/S cash flow conversion efficiency. Based on the latest financial reports, Novo Nordisk A/S (NOVO-B) has a cash flow conversion efficiency ratio of 0.039x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr7.62 Billion ≈ $1.19 Billion USD) by net assets (Dkr194.05 Billion ≈ $30.36 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Novo Nordisk A/S (1990–2025)
Cash flow conversion efficiency of Novo Nordisk A/S from 1990 to 2025. This chart illustrates how Novo Nordisk A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NOVO-B stock price and chart for real-time trading data and today's change.
Novo Nordisk A/S Cash Flow Conversion Ratio Explained
Novo Nordisk A/S cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Novo Nordisk A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novo Nordisk A/S ranked by their cash flow conversion efficiency. Also see NOVO-B stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Salesforce.com Inc
NYSE:CRM
|
0.196x |
|
Uber Technologies Inc
NYSE:UBER
|
0.103x |
|
Honeywell International Inc
NASDAQ:HON
|
0.076x |
|
Welltower Inc
NYSE:WELL
|
0.015x |
|
Southern Copper Corporation
NYSE:SCCO
|
0.156x |
|
ALLIANZ SE UNSP.ADR 1/10
F:ALVE
|
N/A |
|
Allianz SE VNA O.N.
XETRA:ALV
|
0.316x |
|
Sumitomo Mitsui Financial Group Inc
F:XMFA
|
N/A |
Annual Cash Flow Conversion Efficiency for Novo Nordisk A/S (1990–2025)
The table below shows the annual cash flow conversion efficiency of Novo Nordisk A/S from 1990 to 2025. Review NOVO-B FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Dkr194.05 Billion ≈ $30.36 Billion |
Dkr119.10 Billion ≈ $18.63 Billion |
0.614x | -27.20% |
| 2024-12-31 | Dkr143.49 Billion ≈ $22.45 Billion |
Dkr120.97 Billion ≈ $18.93 Billion |
0.843x | -17.51% |
| 2023-12-31 | Dkr106.56 Billion ≈ $16.67 Billion |
Dkr108.91 Billion ≈ $17.04 Billion |
1.022x | +8.16% |
| 2022-12-31 | Dkr83.49 Billion ≈ $13.06 Billion |
Dkr78.89 Billion ≈ $12.34 Billion |
0.945x | +21.54% |
| 2021-12-31 | Dkr70.75 Billion ≈ $11.07 Billion |
Dkr55.00 Billion ≈ $8.61 Billion |
0.777x | -5.24% |
| 2020-12-31 | Dkr63.33 Billion ≈ $9.91 Billion |
Dkr51.95 Billion ≈ $8.13 Billion |
0.820x | +1.00% |
| 2019-12-31 | Dkr57.59 Billion ≈ $9.01 Billion |
Dkr46.78 Billion ≈ $7.32 Billion |
0.812x | -5.62% |
| 2018-12-31 | Dkr51.84 Billion ≈ $8.11 Billion |
Dkr44.62 Billion ≈ $6.98 Billion |
0.861x | +4.14% |
| 2017-12-31 | Dkr49.81 Billion ≈ $7.79 Billion |
Dkr41.17 Billion ≈ $6.44 Billion |
0.826x | -22.57% |
| 2016-12-31 | Dkr45.27 Billion ≈ $7.08 Billion |
Dkr48.31 Billion ≈ $7.56 Billion |
1.067x | +30.93% |
| 2015-12-31 | Dkr46.97 Billion ≈ $7.35 Billion |
Dkr38.29 Billion ≈ $5.99 Billion |
0.815x | +3.64% |
| 2014-12-31 | Dkr40.29 Billion ≈ $6.30 Billion |
Dkr31.69 Billion ≈ $4.96 Billion |
0.787x | +29.06% |
| 2013-12-31 | Dkr42.57 Billion ≈ $6.66 Billion |
Dkr25.94 Billion ≈ $4.06 Billion |
0.609x | +11.47% |
| 2012-12-31 | Dkr40.63 Billion ≈ $6.36 Billion |
Dkr22.21 Billion ≈ $3.48 Billion |
0.547x | -4.21% |
| 2011-12-31 | Dkr37.45 Billion ≈ $5.86 Billion |
Dkr21.37 Billion ≈ $3.34 Billion |
0.571x | +7.21% |
| 2010-12-31 | Dkr36.97 Billion ≈ $5.78 Billion |
Dkr19.68 Billion ≈ $3.08 Billion |
0.532x | +23.71% |
| 2009-12-31 | Dkr35.73 Billion ≈ $5.59 Billion |
Dkr15.38 Billion ≈ $2.41 Billion |
0.430x | +10.31% |
| 2008-12-31 | Dkr33.06 Billion ≈ $5.17 Billion |
Dkr12.90 Billion ≈ $2.02 Billion |
0.390x | +25.74% |
| 2007-12-31 | Dkr32.22 Billion ≈ $5.04 Billion |
Dkr10.00 Billion ≈ $1.56 Billion |
0.310x | +20.76% |
| 2006-12-31 | Dkr30.13 Billion ≈ $4.71 Billion |
Dkr7.74 Billion ≈ $1.21 Billion |
0.257x | -18.51% |
| 2005-12-31 | Dkr27.59 Billion ≈ $4.32 Billion |
Dkr8.70 Billion ≈ $1.36 Billion |
0.315x | +10.07% |
| 2004-12-31 | Dkr26.69 Billion ≈ $4.18 Billion |
Dkr7.64 Billion ≈ $1.20 Billion |
0.286x | +17.27% |
| 2003-12-31 | Dkr25.29 Billion ≈ $3.96 Billion |
Dkr6.18 Billion ≈ $966.71 Million |
0.244x | +14.69% |
| 2002-12-31 | Dkr22.90 Billion ≈ $3.58 Billion |
Dkr4.88 Billion ≈ $762.97 Million |
0.213x | -0.77% |
| 2001-12-31 | Dkr20.08 Billion ≈ $3.14 Billion |
Dkr4.31 Billion ≈ $674.44 Million |
0.215x | -35.77% |
| 2000-12-31 | Dkr15.75 Billion ≈ $2.46 Billion |
Dkr5.26 Billion ≈ $823.26 Million |
0.334x | +71.52% |
| 1999-12-31 | Dkr18.63 Billion ≈ $2.91 Billion |
Dkr3.63 Billion ≈ $567.93 Million |
0.195x | +1.11% |
| 1998-12-31 | Dkr18.04 Billion ≈ $2.82 Billion |
Dkr3.48 Billion ≈ $543.78 Million |
0.193x | +15.51% |
| 1997-12-31 | Dkr18.17 Billion ≈ $2.84 Billion |
Dkr3.03 Billion ≈ $474.36 Million |
0.167x | +39.10% |
| 1996-12-31 | Dkr16.02 Billion ≈ $2.51 Billion |
Dkr1.92 Billion ≈ $300.66 Million |
0.120x | -31.64% |
| 1995-12-31 | Dkr14.42 Billion ≈ $2.26 Billion |
Dkr2.53 Billion ≈ $395.82 Million |
0.175x | -13.47% |
| 1994-12-31 | Dkr13.13 Billion ≈ $2.05 Billion |
Dkr2.66 Billion ≈ $416.62 Million |
0.203x | +26.76% |
| 1993-12-31 | Dkr11.95 Billion ≈ $1.87 Billion |
Dkr1.91 Billion ≈ $299.16 Million |
0.160x | +27.15% |
| 1992-12-31 | Dkr10.56 Billion ≈ $1.65 Billion |
Dkr1.33 Billion ≈ $207.76 Million |
0.126x | +0.76% |
| 1991-12-31 | Dkr9.50 Billion ≈ $1.49 Billion |
Dkr1.19 Billion ≈ $185.60 Million |
0.125x | -41.66% |
| 1990-12-31 | Dkr7.03 Billion ≈ $1.10 Billion |
Dkr1.50 Billion ≈ $235.32 Million |
0.214x | -- |
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products i… Read more